LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

LLY

765.39

+2.52%↑

JNJ

176.33

-0.45%↓

ABBV

216.67

+0.17%↑

UNH

341.11

-2.21%↓

AZN

77.87

-0.12%↓

Inicio・Lista de Acciones・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Abierto

SectorSalud

35.84 0.42

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

35.42

Máximo

36.18

Métricas clave
By Trading Economics
Ingresos	-20M -85M
Margen de beneficio	-867.293
Empleados	316
EBITDA	-21M -94M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+48.18% upside

Dividendos
By Dow Jones
Próximas Ganancias	11 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	327M 2.9B
Apertura anterior	35.42
Cierre anterior	35.84

Noticias sobre sentimiento de mercado

By Acuity

50%

183 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

34.81 / 38.24 Soporte y Resistencia

Xenon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 sept 2025, 22:39 UTC

Adquisiciones, fusiones, absorciones

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept 2025, 16:43 UTC

Principales Movimientos del Mercado

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept 2025, 16:42 UTC

Principales Movimientos del Mercado

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept 2025, 16:35 UTC

Principales Movimientos del Mercado

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept 2025, 22:48 UTC

Charlas de Mercado

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Expects Commercial Launch in 2029

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 sept 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept 2025, 19:14 UTC

Charlas de Mercado

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept 2025, 18:16 UTC

Charlas de Mercado

Gold Powers to New High -- Market Talk

15 sept 2025, 18:05 UTC

Charlas de Mercado

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept 2025, 17:50 UTC

Adquisiciones, fusiones, absorciones

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept 2025, 17:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 17:10 UTC

Charlas de Mercado

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept 2025, 16:52 UTC

Charlas de Mercado

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado

Ganancias

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

48.18% repunte

Estimación a 12 meses

Media 53.33 USD 48.18%

Máximo 60 USD

Mínimo 48 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentimiento

By Acuity

183 / 371 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.